Business Update Neutral

2026-05-28 18:31

Alkem Laboratories Limited announced on May 28, 2026, that the audio recording of its Q4FY2026 and FY2026 Earnings Conference Call is available on the company's website at https://www.alkemlabs.com/investors/earnings-call, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Routine Neutral

2026-05-28 13:45

Alkem Laboratories Ltd. announced the opening of its trading window from June 1, 2026, following the communication of the financial results for the quarter and year ended March 31, 2026, to the Stock Exchanges on May 28, 2026.

Financials Positive

2026-05-28 13:39

The Board of Directors of Alkem Laboratories Ltd. approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2026. The board recommended a final dividend of Rs. 10 per equity share for the financial year ended 31st March, 2026, to be approved at the 52nd Annual General Meeting (AGM) scheduled for August 27, 2026. The record date for the dividend is August 07, 2026. The Auditors expressed an unmodified opinion on the financial results.

Financials Positive

2026-05-28 13:35

The Board of Directors of Alkem Laboratories Ltd. approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. A final dividend of Rs. 10 per equity share for the financial year ended March 31, 2026, was recommended. The 52nd Annual General Meeting (AGM) will be held on August 27, 2026, with the record date for dividend payment fixed as August 7, 2026, and payment from September 1, 2026. Mrs. Madhurima Singh was also re-appointed as an Executive Director for five years.

Financials Positive

2026-05-28 13:35

Alkem Laboratories Ltd.'s Board of Directors approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of Rs. 10 per equity share for FY 2025-26. The 52nd Annual General Meeting (AGM) is scheduled for August 27, 2026, and the re-appointment of Mrs. Madhurima Singh as an Executive Director for five years was also approved.

Governance Neutral

2026-05-28 13:30

Alkem Laboratories Limited's Board of Directors has approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of 5 (five) consecutive years. The re-appointment is effective from 20th December, 2026, until 19th December, 2031, and is subject to the approval of shareholders at the ensuing Annual General Meeting.

Financials Positive

2026-05-28 13:26

Consolidated Revenue ₹3,603.32 Cr vs ₹3,143.75 Cr (▲14.61% YoY), EBITDA ₹517.39 Cr vs ₹391.29 Cr (▲32.22% YoY), PAT ₹236.46 Cr vs ₹305.86 Cr (▼22.69% YoY). EBITDA Margin 14.36% vs 12.45% (▲191bps). The Board also recommended a final dividend of Rs. 10 per equity share for FY26.

Business Update Neutral

2026-05-25 11:56

Alkem Laboratories Ltd. announced an in-person, one-on-one meeting with SBI Mutual Fund scheduled for May 29th, 2026, in Mumbai. This is an Analyst / Institutional Investor Meeting.

Business Update Neutral

2026-05-20 15:45

Alkem Laboratories Ltd. announced a conference call for investors and analysts to discuss its Q4FY26 and FY26 financial results. The call is scheduled for Thursday, May 28, 2026, at 4:30 p.m. IST, with key management personnel including the MD, CEO, and CFO participating. Motilal Oswal Securities Ltd. will host the call.

Governance Positive

2026-05-18 12:37

Alkem Laboratories Ltd. announced the appointment of Mr. Chanakya Misra to a senior management position, effective 18th May 2026. Mr. Misra brings over 25 years of professional experience across pharmaceuticals, public health, rare diseases, and healthcare ecosystems, holding an MBA and a Bachelor of Pharmacy from IIT (BHU).

Business Update Positive

2026-05-08 18:42

Alkem Laboratories Ltd. announced that the US FDA conducted an unannounced inspection at its Contract Research Organization (CRO) facility in Taloja, Maharashtra, on May 8, 2026. At the conclusion of the inspection, no Form 483 was issued, indicating a satisfactory outcome and compliance with regulatory standards.

Business Update Positive

2026-05-05 18:51

Alkem Laboratories Ltd. received a favourable Order-in-Appeal on May 4, 2026, from Commissioner (Appeals) -II CGST & C.Ex, Mumbai. The order dropped a GST demand of ₹69.65 crore, along with applicable interest and penalty, related to alleged incorrect availment of ITC/GST refund. The company stated there is no material impact on its financial, operational, or other activities.

Business Update Negative

2026-05-02 12:53

CRITICAL RED FLAG DETECTED

Alkem Laboratories Ltd. announced that its manufacturing facility at Amaliya, Daman, underwent a US FDA inspection from April 20th to May 1st, 2026. At the conclusion of the inspection, the company received a Form 483 with seven (7) observations. The company committed to addressing these observations within the stipulated timeframe.

Business Update Negative

2026-04-24 16:43

CRITICAL RED FLAG DETECTED

Alkem Laboratories received an Income Tax order on April 24, 2026, for AY 2023-24, disallowing ₹333.38 Cr in deductions and adjustments. The company states no material financial impact due to MAT credit and will appeal the order, believing it's not tenable.

Routine Neutral

2026-04-24 15:30

New Filing detected. See link for details.

Governance Negative

2026-04-24 14:34

CRITICAL RED FLAG DETECTED

Alkem Laboratories announced the resignation of Dr. Vikas Gupta, Chief Executive Officer and Key Managerial Personnel, to pursue new professional opportunities. He will continue until June 30, 2026, to ensure a smooth transition of responsibilities.

Business Update Positive

2026-04-13 15:39

Alkem Laboratories Limited has incorporated a Wholly Owned Subsidiary, 'Alkem Pharma Trading FZCO', in Dubai, UAE. This WOS, with 100% shareholding and a capital of AED 3,670,000, aims to export the Company's products to African, South East Asian, and non-UAE markets.

Routine Neutral

2026-04-10 18:08

New Filing detected. See link for details.

Business Update Positive

2026-04-07 15:27

Alkem Laboratories Ltd. launched 'A to Z Daily' on April 7, 2026, a multivitamin supplement for adults. It provides holistic nutritional support, formulated with 26 essential vitamins, minerals, and botanicals to help manage stress, improve energy, and strengthen immunity.

Ownership Neutral

2026-04-07 14:30

Basudeo N. Singh, promoter of Alkem Laboratories Limited, declared that the promoter group has not made any encumbrance on shares, directly or indirectly, during the financial year 2025-26, as per SEBI SAST Regulation 31(4).

Business Update Positive

2026-04-02 13:00

Alkem Laboratories' Board on April 2, 2026, approved increasing the investment for its greenfield formulations manufacturing facility in Ujjain from up to INR 533 crores to up to INR 1036 crores. This expanded investment will be made in a phased manner.

Governance Neutral

2026-03-31 18:47

Alkem Laboratories Ltd. announced Mr. Ravinder Chaklam superannuated from senior management on March 24, 2026. Mr. Mukesh Tiwari also ceased senior management position in the company on Oct 1, 2025, following his appointment in a wholly-owned subsidiary. Disclosure was delayed due to oversight.

Business Update Neutral

2026-03-30 17:37

Alkem Laboratories Ltd. incorporated 'Alkem Pharmaceuticals Scientific Office FZ LLC' as a Wholly Owned Subsidiary in Dubai Healthcare City, UAE, on Feb 4, 2026. The WOS, with AED 3.67M capital, will handle manufacturing and product registrations. Approvals from UAE's Ministry of Health are delayed due to regional conflict.

Governance Neutral

2026-03-27 18:11

Alkem Laboratories Limited announced the appointment of Mr. Samsher Kumar Deo as Senior Management Personnel, effective March 27, 2026. Mr. Deo has over 29 years of experience, mainly in sales functions.

Routine Neutral

2026-03-27 11:26

Alkem Laboratories Limited announced the closure of its trading window from March 30, 2026, until 48 hours after the communication of financial results for the quarter and year ended March 31, 2026, to the stock exchanges.

Business Update Positive

2026-03-21 12:17

Alkem Laboratories launched Semaglutide injection in India on March 21, 2026, for type-2 diabetes and chronic weight management under brand names "Semasize", "Obesema", and "Hepaglide". Weekly therapy starts at INR 450/-, aiming to provide an affordable and accessible treatment option.

Business Update Positive

2026-03-20 21:19

Alkem Laboratories received an EU GMP Certificate from the Malta Medicines Authority for its Daman manufacturing facility, valid for three years from December 09, 2025. This ensures compliance for manufacturing activities.

Business Update Neutral

2026-03-20 17:09

Alkem Laboratories Ltd. informed of a virtual analyst/institutional investor meeting with Millennium Capital Management scheduled for March 26, 2026, to discuss the company's business.

Business Update Positive

2026-03-18 19:57

Alkem Laboratories received an allotment letter on March 18, 2026, for 30 acres in Ujjain, MP, to set up a new greenfield manufacturing facility. The Board approved an investment of up to ₹533 crores in a phased manner.

Business Update Positive

2026-03-14 15:45

Alkem Laboratories received an EU GMP Certificate for its Baddi manufacturing facility from the Department of Pharmacy (Human Medicines) – Germany, following a November 2025 inspection. The certificate is valid for three years, ensuring continued compliance for European market access.

Business Update Positive

2026-03-06 15:38

Alkem Laboratories' wholly-owned subsidiary, Alkem Medtech, has executed a Share Purchase Agreement on March 6, 2026, to acquire a 51% to 55% equity stake in Switzerland-based Occlutech Holding AG. This updates the previous intimation from February 13, 2026.

Business Update Neutral

2026-02-20 18:31

Alkem Laboratories announced on February 20, 2026, that the video recording of an investor meet discussing Alkem MedTech's strategic way forward is now available on the company's website for investor access.

Business Update Positive

2026-02-18 12:53

Alkem Laboratories Ltd. submitted an updated investor meet presentation on Alkem MedTech's strategic way forward, held on February 18, 2026. The presentation introduces the CEO and key team, highlighting therapeutic areas for the MedTech division.

Business Update Neutral

2026-02-17 17:17

Alkem Laboratories announced scheduled in-person analyst/investor meetings on February 25, 2026, with Kotak - Chasing Growth 2026, and on February 26, 2026, with IIFL 17th Entrepreneurial India Conference 2026 in Mumbai.

Business Update Positive

2026-02-16 19:45

Alkem Laboratories filed an investor meet presentation on Feb 18, 2026, outlining Alkem MedTech's strategic way forward. It emphasizes the MedTech market opportunity, projected to reach $870B globally by 2030, with India growing at 13% p.a., leveraging competitive advantages.

Business Update Positive

2026-02-16 17:14

Transcript of the Q3 FY26 Earnings Conference Call, held on February 13, 2026. The company reported 10.7% YoY revenue growth, 9% YoY EBITDA growth, and 1.6% YoY net profit growth (impacted by an exceptional item). Management also discussed positive outlook for the new MedTech business.

Business Update Negative

2026-02-16 15:05

CRITICAL RED FLAG DETECTED

USFDA completed a Pre-Approval Inspection (PAI) at Alkem's subsidiary, Enzene Biosciences, on Feb 13, 2026, issuing a Form 483 with 6 procedural observations. Critically, zero observations were related to data integrity. Enzene is preparing corrective actions.

Business Update Negative

2026-02-14 12:02

CRITICAL RED FLAG DETECTED

USFDA issued Form 483 with 6 procedural observations after a Pre-Approval Inspection at Alkem's subsidiary Enzene Biosciences' facility. The company noted zero observations related to data integrity. Enzene is preparing a response to address the observations.

Business Update Positive

2026-02-13 20:02

Alkem Laboratories Ltd. announced an investor meet on February 18, 2026, at 4:30 PM to outline Alkem MedTech's strategic way forward. Senior leadership will be present at the event in Mumbai.

Business Update Neutral

2026-02-13 19:35

Alkem Laboratories Ltd. announced the availability of the audio recording for its Q3&9MFY26 Earnings Conference Call on the company's website (https://www.alkemlabs.com/investors/earnings-call), as per SEBI regulations.

Business Update Positive

2026-02-13 14:39

Alkem MedTech, a wholly-owned subsidiary of Alkem Laboratories, announced its strategic intent to acquire up to 55% stake in Occlutech Holding, Switzerland, for EUR 99.4 million (approx. INR 1,074 crore). This move aims to build a global footprint and enter the advanced cardiovascular devices market. Completion is expected by June 2026, subject to approvals.

Business Update Neutral

2026-02-13 14:18

Alkem Laboratories Ltd. issued a revised intimation for its Q3FY26 and 9MFY26 financial results conference call on February 13, 2026, at 5:00 pm IST, informing about a change in conference call participants.

Routine Neutral

2026-02-13 14:16

Alkem Laboratories announced the opening of its trading window on 16th February, 2026, following the communication of financial results for the quarter and nine months ended 31st December, 2025, to the Stock Exchanges today, 13th February, 2026.

Financials Positive

2026-02-13 14:14

Consolidated Revenue ₹37,368Mn vs ₹33,756Mn (▲10.7% YoY), EBITDA ₹8,280Mn vs ₹7,600Mn (▲9.0% YoY), PAT ₹6,360Mn vs ₹6,260Mn (▲1.6% YoY). EBITDA Margin 22.2% vs 22.5% (▼30bps). The company also announced an acquisition and plans for a GLP-1 semaglutide launch.

Business Update Positive

2026-02-13 14:09

Alkem Laboratories' wholly-owned subsidiary, Alkem Medtech, will acquire 51-55% of Occlutech Holding AG, a Swiss medical device company specializing in cardiac implants. The cash acquisition, valued at EUR 180.70 million, provides Alkem entry into the advanced cardiovascular devices segment. Completion is expected by June 30, 2026.

Business Update Positive

2026-02-13 14:07

Alkem Laboratories' Board approved an amendment to the Shareholders' Agreement for its Saudi Arabia Joint Venture on Feb 13, 2026. The 49% stake initially held by Mr. Abdulaziz Alsheikh will now be held by his wholly-owned company, Vitals Biotech Company.

Business Update Positive

2026-02-13 14:05

Alkem Laboratories informed about an Amendment cum Supplemental Agreement dated Feb 13, 2026, for its subsidiary Enzene Biosciences. F-Prime Capital and ERVI Healthcare will infuse ₹26.16 Cr by subscribing to Series B CCPS and equity shares, acquiring a minority stake.

Business Update Positive

2026-02-13 14:03

Alkem Laboratories' Board approved the amalgamation of its wholly-owned subsidiary, Adroit Biomed Limited, with the parent company. This scheme aims to consolidate business operations, enhance efficiency, reduce costs, simplify the group structure, and leverage resources for growth, subject to NCLT and shareholder approvals.

Financials Neutral

2026-02-13 14:00

Consolidated Revenue ₹3,736.82Cr vs ₹3,374.28Cr (▲10.7% YoY), EBITDA ₹775.21Cr vs ₹759.39Cr (▲2.1% YoY), PAT ₹653.03Cr vs ₹640.79Cr (▲1.9% YoY). EBITDA Margin 20.75% vs 22.51% (▼176bps). An Interim Dividend of Rs. 43/- per share was declared.

Financials Positive

2026-02-13 13:58

Consolidated Revenue from Operations ₹3,736.82Cr vs ₹3,374.28Cr (▲10.74% YoY), EBITDA ₹775.21Cr vs ₹759.39Cr (▲2.08% YoY), PAT attributable to owners ₹636.02Cr vs ₹625.82Cr (▲1.63% YoY). EBITDA Margin 20.74% vs 22.50% (▼176bps). An interim dividend of ₹43 per share was also declared.

Financials Positive

2026-02-13 13:56

Consolidated Revenue ₹3,736.8Cr vs ₹3,374.3Cr (▲10.7% YoY), EBITDA ₹828.0Cr vs ₹759.4Cr (▲9.0% YoY), PAT ₹636.0Cr vs ₹625.8Cr (▲1.6% YoY). EBITDA Margin 22.2% vs 22.5% (▼30bps). An interim dividend of ₹43 per share was declared.

Financials Positive

2026-02-13 13:51

Consolidated Revenue ₹3,736.82 Cr vs ₹3,374.28 Cr (▲10.7% YoY), EBITDA ₹775.21 Cr vs ₹759.39 Cr (▲2.1% YoY), PAT ₹653.03 Cr vs ₹640.79 Cr (▲1.9% YoY). EBITDA Margin 20.75% vs 22.50% (▼175 bps). An interim dividend of ₹43 per share was declared.

Routine Neutral

2026-02-12 11:08

New Filing detected. See link for details.

Business Update Positive

2026-02-06 13:53

Alkem Laboratories Limited's subsidiary Alkem Medtech Private Limited (AMPL) approved the amalgamation of its wholly-owned subsidiary Alkem Medtech Ortho Private Limited (AMOPL) into AMPL on Feb 6, 2026. The merger aims to integrate and consolidate business operations, reduce overheads, and simplify the group structure.

ALKEM

Alkem Laboratories Limited

Filing History

Unlock Full History